Publications

Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain.
Author: Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, Major EO: Clin Microbiol Rev 2012, 3:471-506. PMID: 22763635

Predicting Risk of Progressive Multifocal Leukoencephalopathy from Natalizumab.
Author: Ropper AH. N Engl J Med. 2012; 366 (20): 1938-9. PMID: 22591300

Risk Stratification for Progressive Multifocal Leukoencephalopathy in Patients Treated with Natalizumab.
Author: Sorenson PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC , Montalban X, Olsson T. Mult Scler. 2012; 18(2):143-52. PMID:22312009

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Author: Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. N Engl J Med. 2012 May 17;366(20):1870-80.PMID:22591293

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies.
Author: Major EO. Annu Rev Med. 2010; 61:35-47. PMID: 19719397

Immune Reconstitution is Not a Prognostic Factor in Progressive Multifocal Leukoencephalopathy.
Author: Harrison DM, Newsome SD, Skolasky RL, McArthur JC, Nath A. J Neuroimmunol. 2011; 238 (1-2): 81-6. PMID:21840066

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.
Author: Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B. J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):927-33. PMID:22807558

NINDSHHS LogoN I H logo Usa.gov Logo